Spotlight
Clinical
CME
Partners
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Travoprost 0.004% gets Japan's approval
Japan's Ministry of Health, Labor, and Welfare has approved travoprost ophthalmic solution 0.004% (Travatan Z) for the treatment of glaucoma and ocular hypertension.
Tokyo-Japan's Ministry of Health, Labor, and Welfare has approved travoprost ophthalmic solution 0.004% (Travatan Z) for the treatment of glaucoma and ocular hypertension.
"Travoprost solution provides doctors with a new treatment option that may address an unmet need of many glaucoma patients-a prostaglandin analogue without benzalkonium chloride," Yoshiaki Kitazawa, MD, PhD, and director, Akasaka Kitazawa Eye Clinic, said in a prepared statement.
Japan has the distinction of having the world's second-largest population with glaucoma.
Related Videos
Related Content
